In a recent European Medicines Agency (EMA) announcement, pembrolizumab became the first checkpoint inhibitor to receive approval for the adjuvant treatment of resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. This decision came following the positive results from the phase 3 KEYNOTE-716 trial, which showed that adjuvant pembrolizumab significantly reduced the risk of disease recurrence or death by 40% compared to placebo in patients with completely resected stage II-IIIA NSCLC. This approval marks a significant shift in the standard of care for these patients and underscores the role of immunotherapy in adjuvant settings. With this, patients in Europe now have access to this life-saving treatment option earlier in their disease trajectory.
NOTICE: The story and image of this article are completely ‘hallucinated’ by AI systems, based purely on the title of a real article found on the internet. Names, countries, people, … are purely used on coincidence and chosen by the AI, and are not to be taken seriously.